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Background: Since most hip fractures are related to osteoporo-
sis, treating accelerated bone loss can be an important strategy to
prevent hip fractures. Thiazides have been associated with reduced
age-related bone loss by decreasing urinary calcium excretion.
Objective: To examine the association between dose and dura-
tion of thiazide diuretic use and the risk for hip fracture and to
study the consequences of discontinuing use.
Design: Prospective population-based cohort study.
Setting: The Rotterdam Study.
Participants: 7891 individuals 55 years of age and older.
Measurements: Hip fractures were reported by the general prac-
titioners and verified by trained research assistants. Details of all
dispensed drugs were available on a day-to-day basis. Exposure to
thiazides was divided into 7 mutually exclusive categories: never
use, current use for 1 to 42 days, current use for 43 to 365 days,
current use for more than 365 days, discontinuation of use since
1 to 60 days, discontinuation of use since 61 to 120 days, and
discontinuation of use since more than 120 days.
Results: 281 hip fractures occurred. Relative to nonuse, current
use of thiazides for more than 365 days was statistically signifi-
cantly associated with a lower risk for hip fracture (hazard ratio,
0.46 [95% CI, 0.21 to 0.96]). There was no clear dose depen-
dency. This lower risk disappeared approximately 4 months after
thiazide use was discontinued.
Conclusions: Thiazide diuretics protect against hip fracture, but
this protective effect disappears within 4 months after use is
discontinued.
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Hip fractures are associated with substantial morbidityand mortality. The costs of surgery and rehabilitation
are a burden on public health resources, especially because
the incidence of hip fracture increases as the population
ages (1, 2). Most hip fractures are related to osteoporosis,
and treating accelerated bone loss may therefore be an im-
portant strategy to prevent hip fractures (3).
Thiazide diuretics are widely used as antihypertensive
agents. They are inexpensive and effective and have few
important adverse effects (4). Thiazides are thought to pro-
tect against age-related bone loss by reducing urinary cal-
cium excretion (5). This bone-sparing effect could lead to
reduced fracture incidence in patients treated for hyperten-
sion. Several epidemiologic studies have examined the ef-
fect of thiazides on bone mineral density and fracture in-
cidence. Although bone mineral density was found to be
increased in thiazide users, the difference was often small
(6–12). Thiazides were found to have a protective effect on
hip fracture in most studies (9, 12–17), but occasionally an
increased risk was found (18). Most of the studies, how-
ever, had limitations. Some studies included detailed drug-
dispensing data but limited information on potential con-
founders and effect modifiers (15, 18, 19). Other studies
had small patient samples or used only baseline interview
data on thiazide use (9, 12, 16, 20) without accounting for
timing of thiazide use (14, 20, 21). Detailed information
on thiazide dose and duration of use was often absent or
unreliable because no data on day-to-day use were avail-
able. Because of these limitations, it is still unclear how
long thiazides have to be taken to affect fracture incidence
and how long this effect persists after thiazide use is dis-
continued.
We conducted a prospective, population-based cohort
study using detailed drug-dispensing information, as well
as extensive information on potential risk factors, to exam-
ine the association between current and past use of thia-
zides and the incidence of hip fractures in men and women
55 years of age and older. We also studied the effect of
discontinuing thiazide use on fracture risk.
METHODS
Study Sample
This study was conducted as part of the Rotterdam
Study, a prospective, population-based cohort study on the
occurrence and determinants of disease and disability in
elderly persons (22). In 1990, all inhabitants of Ommoord,
a suburb of Rotterdam in the Netherlands, who were 55
years of age or older and had lived in the district for at least
1 year were invited to participate in the study. Of the
10 275 eligible persons, 7983 (78%) participated. Partici-
pants gave informed consent and permission to retrieve
information from medical records. At baseline, between
1990 and 1993, trained interviewers administered an ex-
tensive questionnaire covering socioeconomic background
and medical history, among other topics, during a home
interview. During subsequent visits to the study center,
additional interviewing, laboratory assessments, and clini-
cal examinations were performed. Information on vital sta-
tus is obtained at regular time intervals from the municipal
authorities in Rotterdam. The Medical Ethics Committee
of the Erasmus MC, Rotterdam, the Netherlands, ap-
proved the study.
For the present study, all participants were followed
from 1 June 1991 until they had an incident hip fracture,
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died, or reached the end of the study at 31 December
1999, whichever came first.
Exposure Definition
In the research area, there are 7 fully computerized
pharmacies that are linked to 1 network. During the study,
all participants filled their prescriptions in 1 of these 7
pharmacies. Data on all dispensed drugs since 1 January
1991 are available in computerized format on a day-to-day
basis. The data include the date of prescribing, the total
amount of drug units per prescription, the prescribed daily
number of units, product name, and the Anatomical Ther-
apeutic Chemical (ATC) code (23).
The exposure of interest included plain thiazides and
thiazides combined with potassium and potassium-sparing
agents. Although formally not a thiazide, chlorthalidone
was included because it has a similar effect on calcium
excretion. In a previous study, these 2 diuretics did not
differ (12). Therefore, we did not distinguish between
them.
When a hip fracture occurred, the date was defined as
the index date and the cumulative duration of use of thia-
zides on that date was calculated for each participant. Cur-
rent use was defined as use of thiazides at the index date
and was expressed as the number of consecutive days of
use. Past use was defined as use of thiazides after baseline
and before but not on the index date itself. Past use was
expressed as the number of days since discontinuing use.
To study the effect of duration of thiazide use, exposure at
the index date was divided into 7 mutually exclusive cate-
gories, defined a priori: never use, current use for 1 to 42
days, current use for 43 to 365 days, current use for more
than 365 days, discontinuation of use since 1 to 60 days,
discontinuation of use since 61 to 120 days, and discon-
tinuation of use since more than 120 days. We selected the
first duration of 42 days because in the first 6 weeks of
thiazide use, the decrease in circulating volume can cause
dizziness and relative cerebral ischemia. We anticipated
that this might be associated with a transiently increased
risk for falls that should be distinguished from a potentially
protective effect after prolonged use. After 42 days, the
circulating volume in most patients is within normal limits
(24). The duration of more than 365 days was chosen
because trials on incidence of nonvertebral fractures with
use of antiosteoporotic agents, such as bisphosphonates, all
had at least 1 year of follow-up as well. Finally, the dura-
tion of 60 days after discontinuing use was chosen because
it was used in an earlier study (15).
We expressed the prescribed daily dosage during cur-
rent use at the index date as a proportion of the defined
daily dosage (25). The defined daily dosage of thiazide
diuretics is the standard recommended adult daily dosage
for treating patients with hypertension in the Netherlands.
To avoid potential misclassification of exposure at
baseline, we ensured that all participants had potential
pharmacy data for at least 5 months before baseline.
Outcome Definition
The study participants’ general practitioners report all
fatal and nonfatal events, such as fractures, through a com-
puterized system. These data cover about 80% of the study
sample. For participants who were not covered in this sys-
tem, research physicians performed annual checks on the
complete medical records of all general practitioners in the
Rotterdam Study.
Two research physicians independently coded all frac-
tures that occurred during the study period using the
International Classification of Diseases, 10th revision
(ICD-10) (26). A medical expert in the field who was un-
aware of patients’ history and medication use (including
thiazides) reviewed all coded events for a final classification.
Fractures with ICD-10 codes S72.0, S72.1, and S72.2
were included, but pathologic hip fractures (M84.4) and
fractures in prosthetic hips (M96.6) were excluded.
Cofactors
The following baseline patient characteristics, all de-
termined by interview, were individually assessed as poten-
tial confounders: age, sex, score on the Mini-Mental State
Examination (26 points) (27), use of a walking aid, any
fracture in the past 5 years, history of hysterectomy, thy-
roid disease, frequency of falling (once per month), cur-
rent smoking, intake of alcohol (2 g/d), and dizziness.
Participants were interviewed about a previous diagnosis of
Parkinson disease or use of antiparkinsonian drugs and
were screened for symptoms of Parkinson disease by study
physicians at the research center. Diabetes mellitus was
defined as the use of glucose-lowering medication or a ran-
dom or postload serum glucose level of 11.1 mmol/L (200
mg/dL) or greater. Hypertension (systolic blood pres-
sure 160 mm Hg, diastolic blood pressure 95 mm
Hg, or use of any antihypertensive drug), visual impair-
ment in 1 or both eyes, and body mass index (kg/m2) were
Context
Thiazide diuretics reduce urinary calcium excretion and
increase bone mineral density, but do they prevent bone
fractures?
Contribution
In this population-based cohort study of 7891 older
adults, patients taking thiazides for more than 1 year had
a lower risk for hip fracture than those not taking thiazides
(hazard ratio, 0.46 [95% CI, 0.21 to 0.96]). Within 4
months of stopping thiazides, the risk for hip fracture
returned to its pretreatment value.
Implications
Thiazide diuretics may reduce hip fractures. Whether they
have effects similar or additive to those of other bone
protective agents merits study.
–The Editors
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measured at the research center. Presence of peripheral ar-
terial disease was measured (as described elsewhere [28]) by
using a single measurement of systolic blood pressure taken
at both the left and the right posterior tibial artery. The
ratio of the systolic blood pressure at the ankle to the sys-
tolic blood pressure at the arm was calculated for each leg.
Peripheral arterial disease was considered present when the
blood pressure at the arm was lower than 0.9 mm Hg on at
least 1 side. Lower-limb disability was assessed by using a
modified version of the Stanford Health Assessment Ques-
tionnaire (29) and by calculating the mean score of answers
to questions about rising, walking, bending, and getting in
and out of a car (30). A score of 0 indicates no disability, a
score between 0 and 1 indicates mild disability, and a score
of more than 1 indicates severe disability. Intake of calcium
was adjusted for the total caloric intake according to the
method of Willett and associates (31). Bone mineral den-
sity of the femoral neck was measured by using dual-energy
x-ray absorptiometry (DPX-L densitometer, Lunar Corp.,
Madison, Wisconsin), as described elsewhere (32). Bone
mineral density was stratified by dividing the study sample
at the median observation (0.71 g/cm2).
Use of other medications, such as corticosteroids, ben-
zodiazepines, antidepressants, antihistamines, opioids, ant-
acids, antipsychotics, statins, and estrogens, was analyzed as
a potential confounder.
Statistical Analysis
Since exposure to thiazides may vary over time, we
calculated risks for hip fracture with a Cox proportional
hazards model (33), with the exposure represented by time-
varying covariates. The model compared the exposure to
thiazides on the index date of each participant with an
incident hip fracture with all other participants in the co-
hort who were alive and at risk for hip fracture at the index
date. We also used time-dependent categorical variables to
compare duration of current use with time since last use.
The 7 exposure categories of continuous use in days are
represented in the model by 6 dummy variables with “nev-
er use” as a reference category. Use of other prescribed
Table 1. Baseline Characteristics of Participants with Hip Fracture and the Total Study Sample*
Characteristic Participants with Hip
Fracture (n  281)
Total Participants
(n  7891)
Participants with
Missing Values
Sex, n (0)
Men 60 3071
Women 221 4820
Age, y 78.24  8.61 68.93  9.90 (0)
Subgroups, n
55–64 y 21 3022
65–74 y 66 2592
75–84 y 121 1658
85 y 73 619
Femoral neck BMD, g/cm2 0.71  0.124 0.84  0.137 (26)
Subgroups, n
0.89 g/cm2 11 1845
0.78–0.89 g/cm2 36 1993
0.78 g/cm2 106 1972
Mean BMI, kg/m2 25.74  3.60 26.28  3.74 (13)
Mean weight, kg 68.39  11.12 72.99  11.96 (12)
Lower-limb disability, n (3)
None 47 3584
Mild 109 2850
Severe 109 1207
MMSE score  26, n 89 1102 (10)
Hypertension, n 102 2612 (10)
Parkinson disease, n 6 75 (3)
Thyroid disease, n 31 691 (8)
Diabetes mellitus, n 39 802 (15)
Visual impairment, n 40 523 (19)
Peripheral arterial disease, n 74 1210 (19)
History of fracture, n 58 1074 (7)
History of hysterectomy, n 16 456 (6)
Use of a walking aid, n 82 839 (8)
Dizziness, n 56 1261 (13)
Current smoking, n 58 1725 (4)
Recent falling, n 78 1336 (3)
Estrogen use at baseline, n 2 101 (27)
Calcium intake, n (31)
Upper two tertiles (958 mg/d) 82 3618
Lower tertile (958 mg/d) 44 1804
Mean alcohol intake, g/d 8.2  12.5 10.3  15.2 (31)
* Values in parentheses are percentages; values expressed with plus/minus signs are means  SD. BMD  bone mineral density; BMI  body mass index; MMSE Mini-
Mental State Examination.
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drugs was also analyzed as a time-dependent categorical
variable. We did a trend analysis on the exposure categories
for current use.
To adjust for potential confounders, cofactors associ-
ated with the occurrence of hip fracture were included in
the age- and sex-adjusted model if doing so caused a
change in the point estimate of more than 5%. Because
bone mineral density is a potential intermediate factor in
the cause– effect relationship of thiazides and hip fractures,
we selected only participants who did not use thiazides at
baseline to study effect modification by femoral neck bone
mineral density. To study whether there was a daily dose–
effect relationship for current users, we divided daily dos-
age into equal to or less than 1.0 defined daily dosage and
higher than 1.0 defined daily dosage and tested the effect
of low-dosage use and high-dosage use against no use in
separate regression analyses. To test an earlier suggestion of
effect modification by low calcium intake (13), we also ran
separate regression analyses for participants with the lowest
tertile of calcium intake at baseline (958 mg/d) versus
participants with higher intake.
Multiple imputation was used to impute missing in-
formation for confounding variables. Five imputation val-
ues were calculated on the basis of the posterior predictive
distribution of the missing values, and 5 complete data sets
were created. On each complete set, the statistical analyses
were performed and the point estimates of the 5 data sets
were combined to form 1 average summary statistic. The
variance of the summary statistic is calculated from the
within-imputation variance and the between-imputation
variance. The combined variance accounts for the uncer-
tainty introduced by estimating the missing values (34). All
analyses were performed with SAS software, version 8.2
(SAS Institute, Inc., Cary, North Carolina).
RESULTS
Eighty-four participants died and 8 participants had
an incident hip fracture before 1 June 1991. Therefore, the
study sample included 7891 participants. During a total
follow-up of 58 009 person-years, 281 hip fractures oc-
curred. Table 1 shows baseline characteristics for the par-
ticipants with hip fractures and the entire study sample, as
well as the percentage of missing values for the variables.
When included in a Cox proportional hazards model with
age and sex, body mass index, lower-limb disability, cur-
rent smoking, and estrogen use caused a change in the
point estimate of 5% or more. These variables were there-
fore included in the final model. At baseline, thiazide users
were more likely to be disabled; have a history of dizziness,
diabetes mellitus, and frequent falling; and have had pre-
vious fractures in the past 5 years, but these factors did not
change the point estimate by 5% or more.
The risk for hip fracture for ever use of thiazides (yes
or no) was decreased but did not reach statistical signifi-
cance (hazard ratio, 0.94 [95% CI, 0.72 to 1.24]). The risk
for hip fracture with current use of thiazides, regardless of
duration of use, was also not statistically significant (hazard
ratio, 0.71 [CI, 0.47 to 1.06]). When duration of current
thiazide use (in months) was used as a continuous variable,
there was a statistically significant inverse association be-
tween increased duration and risk for hip fracture (hazard
ratio, 0.99 [CI, 0.97 to 0.99]). Table 2 shows that with
increasing duration of consecutive use among current us-
ers, the adjusted risk for hip fracture was statistically sig-
nificantly reduced to 0.46 for persons exposed to thiazides
for more than 1 year. Although the risk was lower among
persons taking the lowest dose, the difference was not sig-
nificant. We assessed whether the protective effect of thia-
zides persisted after discontinuing thiazide use and found a
nonstatistically significant risk reduction up to 120 days,
after which the hazard ratio returned to 1.0 (Figure).
The strongest protective effect was found in partici-
pants older than 80 years of age, but the difference between
this group and participants younger than 80 years of age
was not statistically significant. The effect of long-term
thiazide use did not differ in participants with lower or
higher bone mineral density. Participants with a higher
intake of calcium had a somewhat larger risk reduction
(Table 3). Because the study included few men with hip
fracture, there was insufficient power to study effect mod-
ification by sex.
To adjust for potential misclassification of duration of
thiazide use at the start of the study, we also did an analysis
in which we excluded all participants (35 case-patients,
849 controls) who used thiazides at baseline (self-reported
users and pharmacy data–derived users) and participants
with less than 365 days of follow-up. We still found a 30%
reduction in incident hip fractures, but because of smaller
numbers of participants, this was no longer statistically sig-
nificant (hazard ratio, 0.72 [CI, 0.29 to 2.15]).
DISCUSSION
In this study, long-term use of thiazides was associated
with a lower risk for hip fractures. Although this associa-
Table 2. Hazard Ratios of Thiazide Use on Hip Fracture
Thiazide Use Participants with
Hip Fracture, n
Hazard Ratio
(95% CI)*
Never use 202 1.00 (reference)
Ever use 79 0.94 (0.72–1.24)
Current use 26 0.71 (0.47–1.06)
Duration of current use
1–42 d 6 1.17 (0.52–2.63)
43–365 d 13 0.81 (0.46–1.42)
365 d 7 0.46 (0.21–0.96)
Daily dosage†
1.0 DDD 3 0.29 (0.09–0.90)
1.0 DDD 4 0.85 (0.32–2.32)
* Adjusted for age, sex, lower-limb disability, body mass index, estrogen use, and
current smoking. DDD  defined daily dosage.
† DDD in current users with 365 days of thiazide use.
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tion was already visible after short-term use, the risk reduc-
tion reached statistical significance only after 1 year of con-
tinuous use. This protective effect occurred independently
of thiazide dose. After discontinuation of thiazide treat-
ment, the protective effect disappeared after 4 months. Be-
cause our study sample was predominantly female, we
could not study effect modification by sex.
With the exception of 1 case–control study in which
thiazides were associated with an increased risk for hip
fracture (18), several other observational studies found that
thiazide use is associated with a lower incidence of hip
fractures (12, 13, 15, 16, 19). Few studies have investi-
gated the duration of the protective effect of thiazides. A
previous study (15) found a decreased risk for fracture for
up to 2 months after discontinuing use, and a case–control
study found an increased risk for hip fracture for any past
use (13). We more precisely assessed the duration of the
protective effect of thiazides after discontinuation of use
and found a risk reduction for up to 4 months after dis-
continuation.
Several studies published over the past decades have
discussed the mechanisms by which thiazides might protect
against hip fracture. First, thiazides can reduce renal cal-
cium excretion, thereby creating a positive calcium balance
(5, 35). Second, by inducing a metabolic alkalosis, thia-
zides can inhibit bone resorption (36, 37). Furthermore, in
vitro studies showed that thiazides directly inhibit osteocal-
cin secretion of osteoblast-like cells (38, 39). Transbøl and
colleagues (21) found an effect of thiazides on bone min-
eral density only in the first 6 months of use, after which
the bone mineral density of thiazide users and placebo us-
ers did not differ statistically significantly. Other studies,
including a randomized, controlled trial, found protective
effects of thiazides on bone mineral density (8, 9, 11), but
these effects were often small. We could not study the
effect of thiazides on bone mineral density because we had
only cross-sectional data. However, if we adjusted for
cross-sectionally measured bone mineral density in 1993, 2
years after the study began, the effect remained. When we
investigated effect modification by calcium intake, we ob-
served a trend toward a larger thiazide effect for partici-
pants with a higher calcium intake. This might suggest that
creating a positive calcium balance is not the only mecha-
nism by which thiazides affect hip fracture risk, because
participants with moderate to high calcium intake also
benefit from thiazides.
Several aspects of validity need to be discussed. Selec-
tion bias is unlikely to have occurred because our study was
prospective and population-based. Although nonpartici-
pants of the Rotterdam Study were slightly older (on aver-
Figure. Hazard ratios and 95% CIs for hip fracture with use of thiazide diuretics.
All estimates were adjusted for age, sex, body mass index, lower-limb disability, current smoking, and estrogen use. *P  0.05 for trend of current use.
Table 3. Risk for Hip Fracture in Participants with More Than
365 Days of Current Thiazide Use: Effect Modification of Age,
Bone Mineral Density, and Calcium Intake
Variable Participants with
Hip Fracture, n/n
Hazard Ratio
(95% CI)*
Age
80 y 4/158 0.53 (0.19–1.43)
80 y 3/123 0.38 (0.12–1.21)
Bone mineral density†
0.71 g/cm2 2/82 0.67 (0.09–4.87)
0.71 g/cm2 2/71 0.62 (0.09–4.55)
Calcium intake‡
958 mg/d 6/199 0.57 (0.13–2.45)
958 mg/d 1/82 0.21 (0.03–1.50)
* The estimates were adjusted for age (d), sex, lower-limb disability, current smok-
ing, body mass index, and estrogen use.
† For investigation of effect modification of bone mineral density, participants
with thiazide use at baseline were excluded.
‡ The calcium intake was adjusted for total caloric intake.
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age, 73 vs. 70 years of age), it is very unlikely that partic-
ipation was conditional on exposure to thiazides. Information
bias is also unlikely, since exposure data were gathered be-
fore disease onset. We used pharmacy records to avoid
potential misclassification of exposure, which was the main
concern in earlier studies that defined exposure as use of
thiazides at a baseline interview. Because we had access to
independent and reliable information about drug exposure,
in particular duration of use and past use, we could inves-
tigate the effect of thiazides for different periods of use. It
is also unlikely that confounding explains our results, be-
cause we adjusted for many known confounders. It is well
known that thiazides can enhance calcium metabolism, but
it is unlikely that general practitioners prescribed thiazides
preferentially to patients to lower their hip fracture risk
during the study period. Confounding by indication can-
not explain our results, because thiazides were prescribed
somewhat more frequently to patients at a higher risk for
hip fracture. This would tend to negate the protective ef-
fect and even indicate a spurious risk increase. Because
there were few men in our study, the effects of thiazides on
hip fracture risk in women probably dominate our results.
Therefore, it is possible that these effects are somewhat
different in men.
Hypertension is a very common medical problem that
often requires long-term treatment. Thiazides are still rec-
ommended as first-choice antihypertensive agents, but the
prescription rate for these drugs has decreased over the past
decade (40). Recently, a randomized trial showed that thi-
azide-type diuretics are superior in preventing major forms
of cardiovascular disease compared with angiotensin-con-
verting enzyme inhibitors and calcium-channel blockers
(41). Thiazides are inexpensive and have few adverse effects
(42). Our results demonstrate that with long-term thiazide
use, incidence of hip fracture can be statistically signifi-
cantly reduced.
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